Remdesivir
338 results (0.286 seconds)
search results
This Week in Virology
Clinical update with Dr. Daniel Griffin
April 20, 2024 (duration 44m)
[from description] ...cinated COVID-19 patients (NEJM) Nirmatrelvir/ritonavir vs. remdesivir for treatment of high risk outpatients (Therapeutic Advances in Infectious Disease) Molnupiravir safety and efficacy (...
[from content:encoded] ...cinated COVID-19 patients (NEJM) Nirmatrelvir/ritonavir vs. remdesivir for treatment of high risk outpatients (Therapeutic Advances in Infectious Disease) Molnupiravir safety and efficacy (...
April 20, 2024 (duration 44m)
[from description] ...cinated COVID-19 patients (NEJM) Nirmatrelvir/ritonavir vs. remdesivir for treatment of high risk outpatients (Therapeutic Advances in Infectious Disease) Molnupiravir safety and efficacy (...
[from content:encoded] ...cinated COVID-19 patients (NEJM) Nirmatrelvir/ritonavir vs. remdesivir for treatment of high risk outpatients (Therapeutic Advances in Infectious Disease) Molnupiravir safety and efficacy (...
Clinical update with Dr. Daniel Griffin
April 6, 2024 (duration 49m)
[from description] ...onvalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, if remdesivir or paxlovid can reduce cardiovascular adverse events and the first finding of the two-year ...
[from content:encoded] ...onvalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, if remdesivir or paxlovid can reduce cardiovascular adverse events and the first finding of the two-year ...
April 6, 2024 (duration 49m)
[from description] ...onvalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, if remdesivir or paxlovid can reduce cardiovascular adverse events and the first finding of the two-year ...
[from content:encoded] ...onvalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, if remdesivir or paxlovid can reduce cardiovascular adverse events and the first finding of the two-year ...
Clinical update with Dr. Daniel Griffin
March 30, 2024 (duration 44m)
[from description] ...es to dispel the myth of viral rebound including that after administration of the “oral remdesivir”, revised guidelines SARS-CoV-2 treatment and how to treat respiratory viral infections, wh...
[from content:encoded] ...es to dispel the myth of viral rebound including that after administration of the “oral remdesivir”, revised guidelines SARS-CoV-2 treatment and how to treat respiratory viral infections, wh...
March 30, 2024 (duration 44m)
[from description] ...es to dispel the myth of viral rebound including that after administration of the “oral remdesivir”, revised guidelines SARS-CoV-2 treatment and how to treat respiratory viral infections, wh...
[from content:encoded] ...es to dispel the myth of viral rebound including that after administration of the “oral remdesivir”, revised guidelines SARS-CoV-2 treatment and how to treat respiratory viral infections, wh...
Clinical update with Dr. Daniel Griffin
January 27, 2024 (duration 54m)
[from description] ... tools (ESMED) How to pay for Paxlovid (PAXCESS) Remdesivir for immunocompromised during variant waves (CID) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for imm...
[from content:encoded] ... tools (ESMED) How to pay for Paxlovid (PAXCESS) Remdesivir for immunocompromised during variant waves (CID) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for imm...
January 27, 2024 (duration 54m)
[from description] ... tools (ESMED) How to pay for Paxlovid (PAXCESS) Remdesivir for immunocompromised during variant waves (CID) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for imm...
[from content:encoded] ... tools (ESMED) How to pay for Paxlovid (PAXCESS) Remdesivir for immunocompromised during variant waves (CID) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for imm...
Clinical update with Dr. Daniel Griffin
November 18, 2023 (duration 46m)
[from description] ...compromised immune system, evaluation of the safety profile and therapeutic efficacy of Remdesivir in children with SARS-CoV-2 infection, effect of neutralizing monoclonal antibody treatment...
[from content:encoded] ...compromised immune system, evaluation of the safety profile and therapeutic efficacy of Remdesivir in children with SARS-CoV-2 infection, effect of neutralizing monoclonal antibody treatment...
November 18, 2023 (duration 46m)
[from description] ...compromised immune system, evaluation of the safety profile and therapeutic efficacy of Remdesivir in children with SARS-CoV-2 infection, effect of neutralizing monoclonal antibody treatment...
[from content:encoded] ...compromised immune system, evaluation of the safety profile and therapeutic efficacy of Remdesivir in children with SARS-CoV-2 infection, effect of neutralizing monoclonal antibody treatment...
Clinical update with Dr. Daniel Griffin
November 4, 2023 (duration 37m)
[from description] ...s compared with seasonal influenza and RSV infections in adults (CID) Remdesivir is associated with reduced mortality in COVID-19 patients requiring oxygen (OFID) Effectiveness of nirmatrel...
[from content:encoded] ...s compared with seasonal influenza and RSV infections in adults (CID) Remdesivir is associated with reduced mortality in COVID-19 patients requiring oxygen (OFID) Effectiveness of nirmatrel...
November 4, 2023 (duration 37m)
[from description] ...s compared with seasonal influenza and RSV infections in adults (CID) Remdesivir is associated with reduced mortality in COVID-19 patients requiring oxygen (OFID) Effectiveness of nirmatrel...
[from content:encoded] ...s compared with seasonal influenza and RSV infections in adults (CID) Remdesivir is associated with reduced mortality in COVID-19 patients requiring oxygen (OFID) Effectiveness of nirmatrel...
Weltspiegel
Die Sendung vom 03. Mai 2020
October 25, 2023
[from description] Niederlande: Helden des Alltags | USA: Corona und Gewalt | USA: Wunder-Mittel Remdesivir? | Island: Mit Massentests aus der Corona-Krise | Portugal: Mit Glück durch die Corona-Kr...
October 25, 2023
[from description] Niederlande: Helden des Alltags | USA: Corona und Gewalt | USA: Wunder-Mittel Remdesivir? | Island: Mit Massentests aus der Corona-Krise | Portugal: Mit Glück durch die Corona-Kr...
Clinical update with Dr. Daniel Griffin
September 2, 2023 (duration 48m)
[from description] ...n XBB.1.5-adapted COVID-19 vaccine in the European Union, clinical antiviral efficacy of Remdesivir in COVID-19, optimal duration of systemic corticosteroids in COVID-19 treatment, clinical ...
[from content:encoded] ...n XBB.1.5-adapted COVID-19 vaccine in the European Union, clinical antiviral efficacy of Remdesivir in COVID-19, optimal duration of systemic corticosteroids in COVID-19 treatment, clinical ...
September 2, 2023 (duration 48m)
[from description] ...n XBB.1.5-adapted COVID-19 vaccine in the European Union, clinical antiviral efficacy of Remdesivir in COVID-19, optimal duration of systemic corticosteroids in COVID-19 treatment, clinical ...
[from content:encoded] ...n XBB.1.5-adapted COVID-19 vaccine in the European Union, clinical antiviral efficacy of Remdesivir in COVID-19, optimal duration of systemic corticosteroids in COVID-19 treatment, clinical ...
Clinical update with Dr. Daniel Griffin
August 5, 2023 (duration 35m)
[from description] ...the point of care, effectiveness of oral Nirmatrelvir/Ritonavir vs. intravenous three-day Remdesivir in preventing progression to severe COVID-19, NIH launching of several phase 2 long-COVID...
[from content:encoded] ...the point of care, effectiveness of oral Nirmatrelvir/Ritonavir vs. intravenous three-day Remdesivir in preventing progression to severe COVID-19, NIH launching of several phase 2 long-COVID...
August 5, 2023 (duration 35m)
[from description] ...the point of care, effectiveness of oral Nirmatrelvir/Ritonavir vs. intravenous three-day Remdesivir in preventing progression to severe COVID-19, NIH launching of several phase 2 long-COVID...
[from content:encoded] ...the point of care, effectiveness of oral Nirmatrelvir/Ritonavir vs. intravenous three-day Remdesivir in preventing progression to severe COVID-19, NIH launching of several phase 2 long-COVID...
Clinical update with Dr. Daniel Griffin
July 29, 2023 (duration 32m)
[from description] ...e variants in SARS-CoV-2 isolates in Ontario, Canada, viral resistance analyses from the Remdesivir phase 3 adaptive COVID-19 treatment trial-1, impact of Molnupiravir treatment on patient-r...
[from content:encoded] ...e variants in SARS-CoV-2 isolates in Ontario, Canada, viral resistance analyses from the Remdesivir phase 3 adaptive COVID-19 treatment trial-1, impact of Molnupiravir treatment on patient-r...
July 29, 2023 (duration 32m)
[from description] ...e variants in SARS-CoV-2 isolates in Ontario, Canada, viral resistance analyses from the Remdesivir phase 3 adaptive COVID-19 treatment trial-1, impact of Molnupiravir treatment on patient-r...
[from content:encoded] ...e variants in SARS-CoV-2 isolates in Ontario, Canada, viral resistance analyses from the Remdesivir phase 3 adaptive COVID-19 treatment trial-1, impact of Molnupiravir treatment on patient-r...
Didn't find, what you are looking for? A podcast, an episode is missing? You can provide a feed-URL, that will be added to the database. You can do that here. In case you think, there's a bug, please contact us. Thanks!